Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan for Prevention of Trastuzumab-Associated Cardiotoxicity
NCT00459771Phase 3Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2007
- Primary completion
- Dec 2013
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cardiotoxicity comparing Placebo with Candesartan (2 arms). Primary endpoint: Decline in Left Ventricular Ejection Fraction (LVEF) at 1 year. Started Jun 2007; status: completed.
02
Drugs
candesartan
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT00459771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00459771.